STARshiP: Screen and Treat with Aspirin to Reduce Pre-eclampsia
Research type
Research Study
Full title
Screen and Treat with Aspirin to Reduce Pre-eclampsia
IRAS ID
320171
Contact name
Jenny Myers
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
2 years, 9 months, 30 days
Research summary
STARshiP is investigating whether a new pre-eclampsia screening test (the FMF test) reduces the risk of preterm birth (birth before 37 weeks gestation) compared to the current NICE (National Institute for Health & Care excellence) screening strategy. The study will also look at which of the two tests is most cost-effective.
Pre-eclampsia is a serious condition that can develop during some pregnancies. It causes high blood pressure and protein in the urine posing risks to the woman/birthing person and the baby, including kidney damage, stroke, or even death. Pre-eclampsia is the leading cause of preterm birth and can lead to serious health challenges for the baby.
Currently, a daily dose of aspirin is recommended for those identified at higher risk via the current NICE method for pre-eclampsia screening. However, this approach is less effective for first-time mothers and individuals from Black and Minority Ethnic backgrounds.
The study will take place in 16 maternity Trusts in the North of England and the Midlands. Initially, hospitals will use the current NICE method for pre-eclampsia screening, and then they will switch to the new screening test. The new test involves a blood test and and ultrasound scan which will be carried out alongside other routine tests. Those identified as high risk for pre-eclampsia by either test will be recommended aspirin as per local guidelines.
The study will look at the impact of each test on preterm births by analysing routinely collected data from national information systems from approximately 220,000 pregnant women/birthing people and their babies. It will compare healthcare costs from both tests to determine which provides better value for money.
The ultimate aim is to improve the accuracy of pre-eclampsia screening and prevent adverse consequences from pre- eclampsia in more women/people by reducing the number of preterm births, potentially saving healthcare costs and in turn improve health outcomes.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
24/EM/0256
Date of REC Opinion
9 Apr 2025
REC opinion
Further Information Favourable Opinion